In a patient with an obstructed infected kidney on ceftazidime‑avibactam, aztreonam, fosfomycin, caspofungin and teicoplanin, with pending repeat blood and urine cultures and a decreasing but still elevated procalcitonin, what is the next best management step?

Management of Obstructed Infected Kidney with Decreasing Procalcitonin

Continue current antimicrobial therapy while awaiting repeat culture results, and reassess daily for potential de-escalation once susceptibility profiles return. The decreasing procalcitonin trend (90→30) indicates clinical improvement, but the patient remains on broad empiric coverage for a serious urologic infection requiring ongoing monitoring.

Immediate Management Steps

Await Culture Results Before Making Changes

• Do not modify the current antimicrobial regimen until repeat blood and urine culture results are available 1
• The Surviving Sepsis Campaign emphasizes that antimicrobial regimens should be reassessed daily, but changes should be guided by culture data and clinical response 1
• Obtaining cultures before any antibiotic modifications is critical, though this should not delay initial therapy 1

Monitor Clinical Response Parameters

• The decreasing procalcitonin (90→30) suggests improving infection control, though levels remain elevated 1
• Procalcitonin can assist in discontinuing empiric antibiotics in patients with no subsequent evidence of infection, but this patient has a documented obstructed infected kidney requiring continued treatment 1
• Continue monitoring fever curve, white blood cell count, renal function, and hemodynamic stability 1, 2

Source Control Considerations

Ensure Adequate Drainage

• Verify that the obstructed kidney has appropriate drainage via nephrostomy tube or ureteral stent 1
• The presence of an obstructed infected kidney represents an undrainable focus that may require longer antimicrobial courses (beyond the typical 7-10 days) 1
• If purulent material was encountered during any intervention, drainage must be maintained and cultures obtained 1

Antimicrobial Stewardship Approach

Daily Reassessment Protocol

• Evaluate all culture results and susceptibility profiles once available to identify the causative pathogen 2
• De-escalation should occur within 3-5 days of initiating empiric combination therapy once susceptibility is known 1, 2
• The current regimen (ceftazidime-avibactam, aztreonam, fosfomycin, caspofungin, teicoplanin) is extremely broad and likely includes redundant coverage 1, 3

Anticipated De-escalation Strategy

• Once cultures identify the organism(s), narrow to the most appropriate single agent or minimal combination that covers the pathogen 1, 2
• For carbapenem-resistant Enterobacteriaceae (CRE), ceftazidime-avibactam monotherapy may be sufficient if susceptible 1, 3
• For metallo-beta-lactamase (MBL) producers, the combination of ceftazidime-avibactam plus aztreonam should be continued 1, 4
• Discontinue antifungal therapy (caspofungin) if no fungal organisms are isolated, as empiric antifungals in urinary infections without documented candidemia do not improve outcomes 1

Dosing Optimization

Renal Function Monitoring

• Reassess renal function daily as patients with obstructed infected kidneys often have fluctuating kidney function 2, 5
• Ceftazidime-avibactam requires renal dose adjustment, and inadequate dosing has been independently associated with higher mortality in KPC-producing infections 6
• Full-dose ceftazidime-avibactam (7.5g daily) is preferred when renal function permits, as reduced dosing is associated with treatment failure 6

Treatment Duration

Extended Course Likely Needed

• Typical sepsis treatment is 7-10 days, but this patient has an obstructed focus requiring longer therapy 1, 2
• Continue antibiotics until clinical cure is achieved: resolution of fever, normalizing inflammatory markers, and improving renal function 1
• Slow clinical response in urologic infections with obstruction warrants extended courses 1

Critical Pitfalls to Avoid

Do Not Prematurely De-escalate

• Avoid narrowing therapy before culture results confirm susceptibility patterns 2
• The decreasing procalcitonin is encouraging but does not eliminate the need for pathogen-directed therapy 1

Avoid Prolonged Broad-Spectrum Coverage

• Once cultures return, prolonged use of the current five-drug regimen increases risk of superinfection with Candida, Clostridioides difficile, or vancomycin-resistant enterococci 2
• Combination therapy beyond 3-5 days without documented need (e.g., MBL-producing organisms) increases toxicity without benefit 1

Monitor for Renal Toxicity

• The combination of multiple nephrotoxic agents (colistin if added, aminoglycosides if considered) with fluctuating renal function in an obstructed kidney requires vigilant monitoring 1, 2